Reported Saturday, Amgen's Repatha Reduces 3-P MACE Risk By 31% In VESALIUS-CV Subgroup Analysis Of 3,655 High-Risk Diabetic Patients Without Prior Heart Attack Or Stroke

Amgen's Repatha has been shown to reduce the risk of three-point major adverse cardiovascular events (MACE) by 31% in a subgroup analysis of 3,655 high-risk diabetic patients without a history of heart attack or stroke, according to findings from the VESALIUS-CV study. This positions Repatha as the only PCSK9 inhibitor that significantly impacts the risk of first cardiovascular events in high-risk primary prevention. The study highlights the benefits of initiating Repatha treatment earlier in these patients, achieving a median LDL-C reduction of 44 mg/dL.